- Demonstrates first-ever commercial product capable of
single-cell RNA sequencing on FFPE tissues
- Opens preorders for CytAssist, the company's first spatial
instrument
- Shares new data on the company's Xenium In Situ Analyzer,
expected to ship by year-end
PLEASANTON, Calif., June 7, 2022
/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences
leader focused on mastering biology to advance human health, today
announced a series of product updates that will be presented at the
2022 Advances in Genome Biology and Technology (AGBT) General
Meeting this week in Orlando, Fla.
The latest developments across 10x Genomics' leading Chromium and
Visium platforms and the highly anticipated Xenium launch expected
later this year showcase the company's leadership and innovation at
the forefront of single-cell analysis, spatial biology, and in
situ technology.
"With major advances in each of our three platforms, we are
executing to make 2022 the most exciting year of product launches
in our history," said Ben Hindson,
Co-founder and Chief Scientific Officer of 10x Genomics. "As the
only company with technologies that cover single cell, spatial and
in situ analysis, we're in the best position to fuel researchers'
discoveries and unlock new biological insights that will ultimately
advance human health. We look forward to demonstrating the power of
10x Genomics' leading platforms, showcasing researchers' success
with our technologies and highlighting our robust product pipeline
at AGBT."
In addition to the new developments announced today, 10x
Genomics will host a workshop at AGBT on Thursday, June 9, at noon Eastern to share
the latest data across its three platforms, including Xenium.
Chromium
As part of the company's robust R&D pipeline, 10x Genomics
is driving innovation to enable broad adoption of the Chromium
single-cell platform by increasing access to more sample types,
removing bottlenecks, and giving researchers a more flexible and
streamlined workflow.
10x Genomics today announced the compatibility of its recently
launched Fixed RNA Profiling Kit to enable single-cell
transcriptomics on dissociated formalin-fixed, paraffin-embedded
(FFPE) tissues. This groundbreaking capability enables single-cell
analysis on preserved biobank samples for the first time ever. FFPE
tissues are ideal for translational and clinical research, yet have
remained inaccessible for single-cell analysis until now.
"Our Chromium platform has fueled thousands of discoveries and
helped profile more than 5 billion cells, accelerating the
scientific community's understanding and mastery of biology," said
Michael Schnall-Levin, Founding
Scientist and Chief Technology Officer at 10x Genomics. "Yet, all
of these insights have been generated in prospective studies
leveraging fresh or fresh-frozen tissues. Now, for the first time
ever, researchers can look retrospectively and analyze FFPE tissues
at single-cell resolution and scale. By opening up the archives for
single-cell analysis, we have the potential to truly transform the
future of health and medicine."
Both the Fixed RNA Profiling Kit and the previously announced
Nuclei Isolation Kit, 10x Genomics' first sample preparation
product, are now shipping.
Visium
10x Genomics announced the launch and pre-order availability of
two new products in its Visium portfolio, the leading spatial
discovery platform:
- Visium CytAssist - The company's first spatial
instrument, Visium CytAssist helps researchers bridge the
world of histology and genomics and enables spatial profiling
insights to be gained from an expanded range of FFPE samples. The
compact, benchtop system simplifies sample processing by
facilitating the transfer of analytes from tissue sections
pre-mounted on standard glass slides to Visium slides.
- Visium for FFPE v2: Demonstrating its continued
commitment to innovation and rapid advancements, 10x Genomics is
launching the second version of its spatial FFPE workflow, less
than one year after releasing the initial Visium for FFPE assay.
Visium for FFPE v2 features several product advancements and
workflow improvements, including the flexibility for larger capture
areas and the ability to profile RNA and dozens of proteins
simultaneously in the same FFPE tissue section at high spatial
resolution. The v2 assay is expected to begin shipping later
this month.
"Spatial genomics takes single-cell characterization to the next
dimension, and 10x Genomics is leading the way in spatial biology
with several new launches that will help further researchers'
understanding of health and disease," said Schnall-Levin. "We are
excited about the breadth of our spatial analysis product roadmap,
which will help further the capabilities of the Visium platform
with new technologies focused on enabling more analytes, more
samples, and greater resolution."
Xenium
Building on its leadership and innovation in single-cell and
spatial analysis, 10x Genomics is planning to launch its Xenium
platform for in situ analysis later this year.
"In situ analysis that allows for true single-cell spatial
resolution is the next frontier of biology, and we're incredibly
excited to launch our Xenium platform later this year," said
Schnall-Levin. "The initial launch is just the beginning for us. We
have an extensive, multi-year product roadmap that will unlock the
full capabilities of the Xenium platform and deliver on the promise
and potential of in situ analysis."
10x Genomics developed the Xenium platform by uniting its
internal development with its 2020 acquisitions of CartaNa and
ReadCoor, which provided intellectual property, key technology
advances, and deep talent and expertise in the emerging in situ
field. To date, the company has more than 200 patents issued and
pending in the in situ field, including key patents for features
related to high throughput and high sensitivity.
At launch, Xenium is expected to offer single-molecule RNA
analysis at subcellular resolution and be compatible with both
fresh frozen and FFPE tissues. In addition, 10x Genomics is
developing Xenium to have the highest throughput of any instrument
in its class.
10x Genomics expects to begin shipping the Xenium Analyzer by
year-end.
Posters
10x Genomics will present five posters during AGBT demonstrating
the use of its platforms to generate novel biological insights.
- Poster #305, Session 1: Barcode Enabled Antigen Mapping (BEAM)
enables next-generation systems immunology analysis of the
post-COVID-19 immune landscape
Presented by Sarah Taylor, Ph.D.,
Director of Applications
- Poster #502, Session 2: High sensitivity single cell RNA
profiling of fixed cells via in situ RNA-templated ligation
Presented by Andrew Kohlway,
Ph.D., Senior Staff Scientist
- Poster #528, Session 2: Unlocking the power of scale with
high-throughput multiomic single cell assays
Presented by Dagmar Walter,
Ph.D., Staff Scientist
- Poster #594, Session 2: A new spin on sample preparation:
rapid, scalable isolation of nuclei for single cell genomics
Presented by Mike Gibbons, Ph.D.,
Senior Scientist
- Poster #600, Session 2: Combining highly multiplexed protein
and transcriptome-wide RNA expression to achieve spatially resolved
multiomic characterization of the tumor microenvironment in FFPE
tissues
Presented by Marlon Stoeckius, Ph.D., Co-Director of R&D,
Stockholm
About 10x Genomics
10x Genomics is a life science technology company building
products to interrogate, understand and master biology to advance
human health. Our integrated solutions include instruments,
consumables and software for analyzing biological systems at a
resolution and scale that matches the complexity of biology. 10x
Genomics products have been adopted by researchers around the world
including in all of the top 100 global research institutions as
ranked by Nature in 2020 based on publications and all of the top
20 global pharmaceutical companies by 2020 research and development
spend and have been cited in over 3,700 research papers on
discoveries ranging from oncology to immunology and neuroscience.
Our patent portfolio comprises more than 1,350 issued patents and
patent applications.
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
as contained in Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the "safe harbor" created by those
sections. All statements, other than statements of historical
facts, may be forward-looking statements. Forward-looking
statements generally can be identified by the use of
forward-looking terminology such as "may," "might," "will,"
"should," "expect," "plan," "anticipate," "could," "intend,"
"target," "project" "contemplate," "believe," "estimate,"
"predict," "potential" or "continue" or variations of them or
similar terminology, but the absence of these words does not mean
that a statement is not forward-looking. These forward-looking
statements include statements regarding 10x Genomics, Inc.'s
expectations regarding our business operations, financial
performance and results of operations, including our expectations
regarding 10x Genomics, Inc.'s product roadmap, as well as our
ability to meet our anticipated cash needs for the foreseeable
future. These statements are based on management's current
expectations, forecasts, beliefs, assumptions and information
currently available to management, and actual outcomes and results
could differ materially from these statements due to a number of
factors. The material risks and uncertainties that could affect 10x
Genomics, Inc.'s financial and operating results and cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release include those
discussed under the captions "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents 10x Genomics, Inc. files
with the Securities and Exchange Commission from time to time.
Although 10x Genomics, Inc. believes that the expectations
reflected in the forward-looking statements are reasonable, it
cannot provide any assurance that these expectations will prove to
be correct nor can it guarantee that the future results, levels of
activity, performance and events and circumstances reflected in the
forward-looking statements will be achieved or occur. These
forward-looking statements do not reflect the potential impact of
any future acquisitions, mergers, dispositions, joint ventures or
investments 10x Genomics may make. Further, as the COVID-19
pandemic is continuously evolving, such forward-looking statements
may not accurately or fully reflect the potential impact that the
COVID-19 pandemic may have on the business, financial condition,
results of operations and cash flows of 10x Genomics, Inc. The
forward-looking statements in this press release are based on
information available to 10x Genomics, Inc. as of the date hereof,
and 10x Genomics, Inc. disclaims any obligation to update any
forward-looking statements provided to reflect any change in our
expectations or any change in events, conditions, or circumstances
on which any such statement is based, except as required by law.
These forward-looking statements should not be relied upon as
representing 10x Genomics, Inc.'s views as of any date subsequent
to the date of this press release.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange
Commission, our website (www.10xgenomics.com), press releases,
public conference calls, public webcasts and our social media
accounts as means of disclosing material non-public information and
for complying with our disclosure obligations under Regulation
FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-advances-leadership-and-innovation-in-single-cell-and-spatial-technologies-at-2022-agbt-general-meeting-301562442.html
SOURCE 10x Genomics, Inc.